Cancer Home > Ofatumumab Dosing
A healthcare provider may recommend ofatumumab (Arzerra®) to people with chronic lymphocytic leukemia (CLL). Specifically, this drug is reserved for those who have not responded to certain other chemotherapy treatment. The dosing guidelines for ofatumumab will be the same for everyone, regardless of age or weight.
This medicine comes as an intravenous (IV) infusion that is administered by a healthcare provider in a healthcare setting. The infusion is given once a week for eight weeks, followed by a dose every four weeks for four doses. Treatment is finished after 12 doses, which normally takes 24 weeks.
(For more information, click Ofatumumab Dosage. This full-length article covers specific dosing guidelines for the drug, as well as details on how this infusion is given and problems to watch out for.)